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Background: Global DNA hypomethylation may result in chro-
mosomal instability and oncogene activation, and as a surrogate
of systemic methylation activity, may be associated with breast
cancer risk. Methods: Samples and data were obtained from
women with incident early-stage breast cancer (I–IIIa) and
women who were cancer free, frequencymatched on age and race.
In preliminary analyses, genomic methylation of leukocyte DNA
was determined by measuring 5-methyldeoxycytosine (5-mdC), as
well as methylation analysis of the LINE-1-repetitive DNA ele-
ment. Further analyses used only 5-mdC levels. Logistic regres-
sion models were used to estimate odds ratios (ORs) and 95%
conﬁdence intervals (CIs) for risk of breast cancer in relation to
amounts of methylation. Results: In a subset of samples tested
(n 5 37), 5-mdC level was not correlated with LINE-1 methyla-
tion. 5-mdC level in leukocyte DNA was signiﬁcantly lower in
breast cancer cases than healthy controls (P 5 0.001), but no
signiﬁcant case–control differences were observed with LINE-1
methylation (P 5 0.176). In the entire data set, we noted signiﬁ-
cant differences in 5-mdC levels in leukocytes between cases
(n 5 176) and controls (n 5 173); P value < 0.001. Compared
with women in the highest 5-mdC tertile (T3), women in the sec-
ond (T2; OR 5 1.49, 95% CI 5 0.84–2.65) and lowest tertile (T1;
OR 5 2.86, 95% CI 5 1.65–4.94) had higher risk of breast can-
cer (P for trend £0.001). Among controls only and cases and con-
trols combined, only alcohol intake was found to be inversely
associated with methylation levels. Conclusion: These ﬁndings
suggest that leukocyte DNA hypomethylation is independently
associated with development of breast cancer.
Introduction
Alterations of DNA methylation, which inﬂuencegene expression and
genome integrity, are an important component of cancer development
(1). Although localized hypomethylation and hypermethylation of
speciﬁc genes has been studied more extensively, global DNA hypo-
methylation is a hallmark of most cancer genomes (2–6), including
breast cancer (7–11). Hypomethylation has been proposed to contrib-
ute to malignancy by activating oncogenes (12,13), inducing genomic
instability (14) and causing chromosome instability (4,15–17).
To date, the majority of methylation studies have used DNA ob-
tained from tumor tissues (2,18), with assessment of differences in
methylation levels between tumor and histologically normal tissue,
for identiﬁcation of methylation markers (18–20). However, the in-
vasiveness of obtaining tumor tissue and the probable existence of
tissue heterogeneity limits the utility of this approach for epidemio-
logic studies. Recently, global hypomethylation in peripheral blood
DNA was noted as an independent risk factor of colorectal, bladder
and head and neck cancer (21–24), presumably causing genomic in-
stability among systemic cells for tumor development (25). Thus,
leukocyte DNA may be a potential surrogate biomarker for systemic
genome methylation status.
Genome-wide DNA hypomethylation derives from the overall level
of 5-methyldeoxycytosine (5-mdC) in dinucleotide CpG sites in the
genome. Since most 5-mdC sites are located in repetitive sequences
that constitute about half of the human genome, and those repetitive
DNA sequences are heavily methylated in normal tissue (4,26,27),
methylation of LINE-1, one of the most prevalent repetitive sequen-
ces, has been used as a surrogate marker for genomic methylation
levels (28).
In the present study, we ﬁrst used both 5-mdC and LINE-1 meth-
odologies to measure methylation levels of blood DNA in a subset of
19 breast cancer cases and 18 controls. Based upon results from the
pilot study, the 5-mdC method was subsequently used in 179 breast
cancer cases and 180 controls to investigate whether genomic meth-
ylation in leukocyte DNA, as a surrogate of systemic methylation
activity, was associated with breast cancer risk. Demographic and
lifestyle factors were considered as potential determinants of methyl-
ation levels and as potential effect modiﬁers of putative associations
between methylation levels and breast cancer risk.
Materials and methods
Study population
Data and samples were obtained from the Roswell Park Cancer Institute
(RPCI) Databank and Biorepository (DBBR), a shared Core resource (29).
In the DBBR, patients newly diagnosed with cancer consent to provide
a blood sample and to complete an in-depth epidemiologic questionnaire
that includes a food frequency questionnaire, information on reproductive
history, family history of cancer,supplement use, comorbidities, prescription
and non-prescription medication use, smoking, alcohol consumption, life-
time physical activity, height and weight from young adulthood to present
and demographic factors. Permission is granted for linkage of data and
samples with medical record information and for use by investigators with
protocols approved by the RPCI Institutional Review Board. Visitors and
family members of patients are consented as healthy controls, who can be
matched by sex, age, residence and race for patients with other types of
cancers. Relationships with patients are noted so that they are not included
in the same population, avoiding overmatching. Blood samples are drawn
p r i o rt os u r g e r yo rc h e m o t h e r a p ya n dprocessed and frozen within 1 h of
phlebotomy. This study of hypomethylation and breast cancer risk was ap-
proved by the RPCI Institutional Review Board.
Study participants
For these analyses, we obtained DNA and data from the DBBR from patients
with early stage (I, II and IIIa) histologically conﬁrmed breast cancer, ages 35–
75. Controls were free of malignant diseases, with the exception of non-
melanoma skin cancer, and were frequency matched to cases on age and race.
DNA was extracted from whole blood using Flexigene kits and was stored at
Abbreviations: CI, conﬁdence interval; DBBR, Databank and Biorepository;
5-mdC, 5-methyldeoxycytosine; OR, odds ratio; RPCI, Roswell Park Cancer
Institute.
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Cases, N 5 179 Controls, N 5 180 P value
a OR (95% CI)
b
Age
30–39 6 (3.4) 8 (4.4)
40–49 43 (24.0) 42 (23.3)
50–59 55 (30.7) 65 (36.1)
60–69 54 (30.2) 47 (26.1)
70þ 21 (11.7) 18 (10.0) P 5 0.764
Race
Caucasian 168 (93.9) 170 (94.4) 1.00
African-American 11 (6.2) 10 (5.6) P 5 0.812 0.91 (0.91–2.21)
Family history of BRCA
No 122 (68.2) 142 (78.9) 1.00
Yes 29 (16.2) 37 (20.6) P 5 0.740 0.89 (0.51–1.54)
Missing 28 (15.6) 1 (0.6)
Menopausal status
Premenopausal 59 (33.0) 73 (40.6) 1.00
Postmenopausal 90 (50.3) 102 (56.7) P 5 0.699 1.00 (0.51–1.98)
Missing 30 (16.8) 5 (2.8)
Education
Below or at high school 41 (22.9) 36 (20.0) 1.00
Above high school 107 (59.8) 143 (79.4) P 5 0.107 0.66 (0.39–1.12)
Missing 31 (17.3) 1 (0.6)
BMI
,25 47 (26.3) 52 (28.9) 1.00
25–29.9 43 (24.0) 63 (35.0) 0.74 (0.43–1.30)
30þ 55 (30.7) 49 (27.2) P 5 0.200 1.27 (0.73–2.24)
Missing 34 (19.0) 16 (8.9)
Smoking habit
Never 75 (41.9) 85 (47.2) 1.00
Ever 74 (41.3) 87 (58.3) P 5 0.870 0.94 (0.61–1.47)
Missing 30 (16.8) 8 (4.4)
Pack-years
Never smoker 75 (41.9) 85 (47.2) 1.00
Below median
c 18 (10.1) 37 (20.6) 0.55 (0.29–1.05)
At or above median 44 (24.6) 39 (21.7) P 5 0.061 1.26 (0.74–2.16)
Missing 42 (23.5) 19 (10.6)
Alcohol consumption habit
Never 36 (20.1) 32 (17.8) 1.00
Ever 115 (64.3) 147 (82.7) P 5 0.182 0.67 (0.39–1.16)
Missing 28 (15.6) 1 (0.6)
Alcohol consumption frequency
Never 36 (20.1) 32 (17.8) 1.00
Below median
d 50 (27.9) 70 (38.9) 0.62 (0.34–1.15)
At or above median 65 (36.3) 77 (42.8) P 5 0.329 0.72 (0.40–1.29)
Missing 28 (15.6) 1 (0.6)
Age at menarche
,13 71 (39.7) 89 (49.4) 1.00
13þ 77 (43.0) 78 (43.3) P 5 0.346 1.22 (0.78–1.91)
Missing 31 (17.3) 13 (7.2)
Age at ﬁrst birth
,25 76 (42.5) 76 (42.2) 1.00
25þ 43 (24.0) 60 (33.3) 0.69 (0.41–1.16)
Nulliparous 28 (15.6) 38 (21.1) P 5 0.356 0.74 (0.41–1.34)
Missing 32 (17.9) 6 (3.3)
Parity
1–2 children 69 (38.6) 74 (41.1) 1.00
3þ 52 (29.0) 64 (35.6) 1.25 (0.69–2.26)
Nulliparous 28 (15.6) 38 (21.1) P 5 0.707 1.06 (0.57–1.97)
Missing 30 (16.8) 4 (2.2)
Age at menopause
e
,50 37 (41.1) 54 (52.9) 1.00
50þ 45 (50.0) 45 (44.1) P 5 0.207 1.41 (0.78–2.54)
Missing 8 (8.9) 3 (2.9)
HRT
e
Never 44 (48.9) 43 (42.1) 1.00
Ever 44 (48.9) 58 (56.7) P 5 0.307 0.73 (0.41–1.30)
Missing 2 (2.2) 1 (1.0)
Multivitamin use
Never or occasionally 67 (37.3) 60 (33.3) 1.00
Regularly 84 (46.9) 118 (65.6) P 5 0.048 0.63 (0.40–0.98)
Missing 28 (15.6) 2 (1.1)
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179 cases, who met the above eligibility criteria, and 180 matched controls.
Global genomic DNA methylation analysis
5-mdC levels were determined by liquid chromatography–electrospray ioniza-
tion tandem mass spectrometry after hydrolysis of DNA (1 lg) as described
previously (30). Brieﬂy, global DNA methylation was expressed as the ratio of
5-mdC to guanine and was determined directly using guanine as the internal
standard based on the assumption that (guanine) 5 (5-mdC) þ (cytosine).
Methylated and unmethylated DNA from colorectal cancer cell line HCT116
andDKO,whichlacks bothDNAmethyltransferasesDNMT1andDNMT3bin
HCT116, was run in every batch as quality control to standardize between
batches by adjusting the difference of methylation level of quality control.
All analyses were done on duplicate samples. Mean coefﬁcient of variation
within 37 subjects was 4.9%.
Quantitative bisulﬁte pyrosequencing
The methylation status of LINE-1-repetitive DNA element was analyzed using
quantitative pyrosequencing of sodium bisulﬁte-converted DNA (31). Primers,
polymerase chain reaction cycling conditions and materials were described
previously (32). Non-CpG cytosines served as internal controls to verify efﬁ-
cient sodium bisulﬁte DNA conversion, and methylated and unmethylated
DNAs were also run as controls. Pyrosequencing was done on duplicate sam-
ples and pyrosequencing assays were performed a minimum of two times.
Statistical analysis
Global methylation levels measured by 5-mdC and LINE-1, which were
normally distributed, were compared using general linear model in 37 sam-
ples (19 cases and 18 controls). In the full study population, after standard-
ization between batches and exclusion of 1% outliers of 5-mdC distribution,
5-mdC levels were normally distributed in both cases (n 5 176) and controls
(n 5 173) assessed by skew and kurtosis test. Continuous variables and
amounts of global methylation were categorized into dichotomous or tertiled
variables based on the distribution among controls. Chi-square test for cat-
egorical variables was used to compare characteristics between cases and
controls. To identify potential predictors of methylation levels and/or factors
that may modify the association between methylation levels and breast can-
cer risk, univariate associations between DNA methylation and each lifestyle
or demographic factor were assessed among controls and among all partic-
ipants after adjustment for case–control status. Age, body mass index, pack-
years of tobacco use, frequency of alcohol intake and parity were assessed as
both continuous and categorical variables. Relationships between methyla-
tion levels and demographic and lifestyle variables were assessed using
standardized b-coefﬁcients. For body mass index, pack-years of tobacco
use, frequency of alcohol intake and parity, categorical variables were en-
tered as continuous variables 0, 1, 2 to determine standardized b-coefﬁcients.
Logistic regression models were used to estimate odds ratios (ORs) and 95%
conﬁdence intervals (CIs) for the association between genomic methylation
levels and breast cancer risk. For potential confounding, we examined known
risk factors for breast cancer, i.e. age (categorical variable, 30–39, 40–49,
50–59, 60–69 and 70þ), race (Caucasian and African-American), family
history of breast cancer (yes and no), menopausal status (premenopausal
and postmenopausal), body mass index (,25, 25–29.9 and 30þ), smoking
habit (never and ever), pack-years (never smoker, below median and at or
above median), alcohol consumption (never and ever), alcohol consumption
frequency (never drinking, below median and at or above median), age at
menarche (,13 and 13þ), age at ﬁrst birth (,25, 25þ and nulliparous),
parity (1–2 children, 3þ and nulliparous) and multivitamin use (never or
occasionally and regularly) (shown in Table I), variables reported to affect
methylation in the literature (age and race) (22,33–36), variables associated
with methylation in the data set (frequency of alcohol consumption) and
laboratory variability (batches). While none of the variables assessed
changed OR estimates by at least 10%, age, race and batch were kept in
all ﬁnal models. Unordered polychotomous logistic regression models were
used to compare different subtype of breast cancer cases. Linear trends for
categorical variables were assessed by a two-sided likelihood ratio test.
Table I. Continued
Cases, N 5 179 Controls, N 5 180 P value
a OR (95% CI)
b
Histological grade
I 18 (10.1)
II 51 (28.5)
III 108 (60.3)
AJCC stage
I 115 (64.3)
II 57 (31.8)
III 7 (3.9)
Hormone status
ERþ/PRþ 111 (62.0)
ERþ/PR  or ER /PRþ 23 (12.9)
ER /PR  41 (22.9)
Tumor size
,1 cm 138 (77.1)
1–2 cm 38 (21.2)
2c m þ 3 (1.7)
Lymph node involvement
No 135 (75.4)
Yes 44 (24.6)
Metastasis
No 179 (100.0)
AJCC, American Joint Committee on Cancer; BMI, body mass index; BRCA, breast cancer; HRT, hormone replacement therapy.
aP value by Chi-square test.
bOR adjusting for age and race.
cMedian pack-year 5 9.7 pack-year.
dMedian total alcohol consumption frequency 5 1.7 per week for alcohol consumption.
eAmong postmenopausal women.
Table II. Comparison of global methylation levels in leukocyte DNA
measured by two methods (N 5 37)
Median Cases, n 5 19 Controls, n 5 18 P value
a
5-mdC 0.001
Mean 3.98 4.33
Median 3.98 4.33
Interquartile range 0.45 0.27
LINE-1 0.176
Mean 74.70 73.90
Median 74.50 73.50
Interquartile range 1.00 1.70
aAssessed by general linear model adjusting for age and race.
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hood ratio test statistics comparing models with and without the cross-
product term.
To assess the dose-response relationship of genomic methylation with breast
cancer risk, a smoothing spline of the predicted ORs as methylation level
increase continuously in the ﬁnal logistic regression model was drawn using
STATA graph. Additionally, global methylation levels were categorized into
four groups using cut off values based on the curve; after stratifying by %
genomic methylation 4.286 that met OR 5 1.0 in the smoothing spline, we cut
off midpoint of methylation range in each strata. Midpoint was 3.809 in the
lower range of 3.332–4.286 below 4.286 of methylation level and 4.843 in the
upper range of 4.286–5.399 above 4.286 of methylation level, respectively.
Thus, the range of each category was 3.332–3.809, 3.809–4.286, 4.286–4.843
and 4.843–5.399, respectively.
All statistical analyses were performed using STATA version 9.0 (Stata
corporation, College Station, TX).
Results
Characteristics of cases and age- and race-matched controls are shown
in Table I. Missing values for demographic and lifestyle variables
were more prevalent in cases compared with controls, but methylation
levels were not signiﬁcantly different between cases with and without
missing data for each variable examined (data not shown). Excluding
missing values, cases and controls did not signiﬁcantly differ on any
characteristics except multivitamin use, although controls tended to
have higher family history of breast cancer, higher education and
more frequent use of hormone replacement therapy than cases.
Global methylation levels were analyzed using both 5-mdC and
LINE-1 among 37 samples randomly selected from the entire group
of study participants as a pilot study. The two markers of global
methylation levels in leukocyte DNAwere not signiﬁcantly correlated
(r 5 –0.204, P 5 0.232 among all participants). 5-mdC levels in
leukocyte DNA were signiﬁcantly lower in 19 breast cancer cases
compared with 18 healthy controls (P 5 0.001). In contrast, LINE-
1 methylation levels were not signiﬁcantly different between cases
and controls (P 5 0.176) (Table II). Based on this preliminary ﬁnd-
ing, we chose the 5-mdC assay for ascertaining global methylation in
the expanded data set.
As shown in Table III, global methylation levels were not associ-
ated with any of the demographic or lifestyle variables examined,
except for an inverse association with frequency of alcohol consu-
mption (never,  median, .median) in controls (b-coefﬁcient 5
 0.078, P 5 0.031) and in cases and controls combined
(b-coefﬁcient 5 –0.053, P 5 0.036), with higher alcohol consump-
tion associated with lower methylation levels. However, frequency of
alcohol consumption did not affect the association between global
methylation and breast cancer risk.
Global methylation levels in leukocyte DNA were signiﬁcantly
lower in breast cancer cases (4.18 ± 0.34) compared with controls
(4.38 ± 0.36; P 5 0.001) (Table IV). Compared with women in the
highest tertile of methylation, women in the second (OR 5 1.49, 95%
CI 5 0.84–2.65) and lowest tertile (OR 5 2.86, 95% CI 5 1.65–
4.94) had higher risk of breast cancer (P for trend , 0.001). Figure
1A shows the dose-response relationship between global leukocyte
DNA methylation levels and breast cancer risk. When groups were
recategorized into those above and below methylation level 4.286%,
corresponding to an OR 5 1 in the smoothing spline, and above and
below midpoints of methylation within these two groups, breast can-
cer risk among those with methylation levels  3.809% had an OR 5
21.84 (95% CI 5 5.22–91.38) compared with those with ,4.843%
methylation (Figure 1B).
When stratiﬁed by demographic and lifestyle factors, associations
between hypomethylation and increased breast cancer risk were stron-
gest among women with a family history of breast cancer (OR 5
5.73, 95% CI 5 1.49–21.97 for ﬁrst tertile versus third tertile, P-
interaction 5 0.345) and those who never smoked (OR 5 6.02, 95%
CI 5 2.29–15.78 for ﬁrst tertile versus third tertile, P-interaction 5
0.084) (Table IV). Associations did not differ by race, age at diagnosis
(median) or alcohol consumption.
Associations with genomic methylation levels did not vary by
tumor characteristics, including histological grade, American Joint
Committee on Cancer TNM stage, hormone status, tumor size and
lymph node involvement in polychotomous model (Table V).
Discussion
In the pilot study, two measures of global methylation in peripheral
blood samples 5-mdC and LINE-1 were not correlated. In the entire
study, mean levels of global methylation, measured as the percentage
of 5-mdC in leukocyte DNA, were signiﬁcantly lower in breast cancer
cases than in controls and were independently associated with in-
creased breast cancer risk in a dose-dependent manner. Except for
frequency of alcohol intake, lifestyle and demographic factors did
not predict methylation levels. However, hypomethylation was sug-
gested as a stronger risk factor for breast cancer among women with
a family history of breast cancer and among never smokers. Methyl-
ation levels were not associated with clinicopathological character-
istics of the breast tumors.
As reviewed by Laird (20), there is no consensus, to date, on the
best technique for assessing methylation proﬁles. Repetitive DNA
sequences (e.g. LINE-1, Alu, SATa and SAT2) are all comparatively
rich in CpG dinucleotides and contain a large portion of total meth-
ylcytosine levels in thegenome (4,26). Thus, genome-wide changes in
DNA methylation are postulated to affect methylation levels in re-
petitive DNA sequences. A previous study reported that methylation
levels in repetitive sequences assessed by methylation-speciﬁc poly-
merase chain reaction techniques using MethylLight were correlated
with 5-mdC levels (37); however, there were no associations between
methylation levels in LINE-1 measured by pyrosequencing and
5-mdC level in our study. A possible reason for this could be differ-
ential sensitivity to detect subtle changes of methylation patterns
between the distinct assays used to measure 5-mdC and LINE-1. In
addition, LINE-1 methylation status is probably not always predictive
of total 5-mdC levels, as the latter measurement reﬂects the overall
contribution of a diverse set of DNA sequence elements including
both CpG island and non-CpG island regions.
Consistent with ﬁndings from this study, genomic DNA hypome-
thylation status in leukocyte DNA has recently been associated with
risk of colorectal, head and neck and bladder cancer (21–24). Lim
et al. (21) reported a dose-dependent inverse association between
global 5-mdC levels and risk of asymptomatic colorectal adenoma
(OR 5 5.8, 95% CI 5 2.0–16.6 for lowest tertile versus highest ter-
tile, P for trend 5 0.002). In the Spanish Bladder Cancer Study,
global methylation levels measured by 5-mdC were also lower among
bladder cancer patients than among controls (OR 5 2.67, 95% CI 5
1.77–4.03). When further stratiﬁed by smoking status, current smok-
ers in the lowest methylation quartile had the highest risk of bladder
cancer compared with never smokers in the highest methylation quar-
tile (OR 5 25.51, 95% CI 5 9.61–67.76, P for interaction 5 0.06)
(22). In another study, hypomethylation of LINE-1 was associated
with increased risk of squamous cell cancer of the head and neck
(OR 5 1.6, 95% CI 5 1.1–2.4) (24). In contrast, Wischwendter
et al. (38) reported that methylation of Alu-repetitive elements in
blood DNA, another surrogate marker correlated with 5-mdC (37),
did not differ between breast cancer cases and controls. We also did
not observe a difference in methylation levels between breast cancer
cases and controls when methylation levels were assessed by LINE-1-
repetitive DNA sequences, although associations with 5-mdC levels
were evident.
Our ﬁndings and others (21–24) indicate that global genomic
hypomethylation of leukocyte DNA may be an independent risk factor
for multiple cancer types, possibly due to resulting genomic instabil-
ity. Lower DNA repair capacity in lymphocytes has been associated
with increased risk of breast cancer (39,40), and genomic instability
measured by micronuclei frequency, levels of DNA single-strand
breaks and alkali-labile lesions, sister chromatid exchange and/or
spontaneous chromosomal aberrations in peripheral blood cells has
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healthy controls and women with benign breast disease (25,41–43).
Global DNA hypomethylation levels in both normal and cancer cells,
however, show the same pattern of hypomethylation with low folate
status (44), and methylation patterns appear to vary between different
cell types (8). Methylation levels are also probably to differ between
cancer DNA and leukocyte DNA; therefore, the use of peripheral
leukocyte DNA methylation as a surrogate marker of genomic insta-
bility in target tumor tissue should be evaluated in further studies.
There are reports that environmental exposure to nutritional, chem-
ical and physical factors can alter methylation status and produce
different phenotypes (45–47). Except for an inverse association be-
tween methylation levels and frequency of alcohol consumption, we
did not ﬁnd any demographic or lifestyle predictors of methylation.
Table III. Predictors of global methylation assessed by univariate general linear model (cases 5 176 and controls 5 173)
Variables Among controls Among all participants (cases þ controls)
Mean ± SE of 5-mdC b P value Mean ± SE of 5-mdC
a b
b P value
b
Total 4.38 ± 0.03 4.28 ± 0.02
Age (continuous) 0.001 0.730 ,0.001 0.996
,Median (55) 4.41 ± 0.04 4.30 ± 0.03
þMedian (55) 4.34 ± 0.04  0.068 0.208 4.26 ± 0.03  0.043 0.263
Race
Caucasian 4.38 ± 0.03 4.27 ± 0.02
African-American 4.41 ± 0.08  0.032 0.781 4.31 ± 0.06  0.036 0.646
Batch (category on date)  0.001 0.776 0.004 0.248
Family history of BRCA
Yes 4.36 ± 0.03 4.27 ± 0.02
No 4.43 ± 0.06 0.069 0.300 4.29 ± 0.05 0.030 0.532
Education
 high school 4.35 ± 0.07 4.25 ± 0.04
.high school 4.38 ± 0.03 0.033 0.624 4.28 ± 0.02 0.036 0.429
BMI (continuous) 0.001 0.790 0.002 0.496
,25 4.37 ± 0.04 4.26 ± 0.03
25–29.9 4.34 ± 0.04 4.26 ± 0.03
30þ 4.39 ± 0.06 0.012 0.730 4.28 ± 0.04 0.009 0.717
Smoking habit
Never 4.38 ± 0.04 4.25 ± 0.03
Ever 4.37 ± 0.04  0.007 0.904 4.30 ± 0.03 0.043 0.272
Pack-year (continuous) 0.001 0.534 ,0.001 0.766
Never smoker 4.38 ± 0.04 4.25 ± 0.03
Below median 4.37 ± 0.06 4.30 ± 0.05
At or above median 4.37 ± 0.06  0.005 0.891 4.27 ± 0.04 0.009 0.716
Alcohol consumption habit
Never 4.45 ± 0.07 4.33 ± 0.05
Ever 4.36 ± 0.03  0.087 0.209 4.26 ± 0.02  0.076 0.109
Alcohol drinking frequency (continuous)  0.004 0.334 Less than –0.001 0.929
Never 4.45 ± 0.07 4.33 ± 0.05
,median 4.42 ± 0.04 4.29 ± 0.03
þmedian 4.30 ± 0.04  0.078 0.031 4.23 ± 0.03  0.053 0.036
Age at menarche
,13 4.41 ± 0.04 4.30 ± 0.03
þ13 4.35 ± 0.04  0.055 0.334 4.26 ± 0.03  0.036 0.375
Age at ﬁrst birth
,25 4.34 ± 0.04 4.28 ± 0.03
þ25 4.36 ± 0.05 4.25 ± 0.03
Nulliparous 4.47 ± 0.06 0.062 0.080 4.31 ± 0.04 0.013 0.596
Parity (continuous)  0.004 0.884  0.002 0.916
Nulliparous 4.47 ± 0.06 4.27 ± 0.04
1–2 4.36 ± 0.04 4.26 ± 0.03
3þ 4.34 ± 0.04  0.062 0.086 4.31 ± 0.03  0.021 0.424
Menopausal status
Premenopausal 4.38 ± 0.04 4.28 ± 0.03
Postmenopausal 4.37 ± 0.04  0.001 0.982 4.27 ± 0.03  0.013 0.736
Age at menopause
Premenopausal 4.38 ± 0.04 4.28 ± 0.03
,50 4.46 ± 0.05 4.31 ± 0.04
þ50 4.27 ± 0.06  0.042 0.220 4.22 ± 0.04  0.026 0.271
HRT
c
Never 4.37 ± 0.03 4.28 ± 0.02
Ever 4.38 ± 0.05 0.015 0.824 4.27 ± 0.04  0.012 0.793
Multivitamin use
Never or occasionally 4.39 ± 0.05 4.31 ± 0.03
Regularly 4.37 ± 0.03  0.004 0.892 4.25 ± 0.03  0.023 0.303
BMI, body mass index; BRCA, breast cancer; HRT, hormone replacement therapy.
aLeast square means adjusted for group (case and control) status.
bAdjusting for group (case and control) status.
cAdjusting for menopausal status.
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1893Table IV. Association between global DNA methylation level classiﬁed by the tertiles of the distribution of controls and breast cancer (cases 5 176 and
controls 5 173)
5-mdC Cases, n (%) Controls, n (%) OR (95% CI)
a
All
b Mean ± SD 4.18 ± 0.34 4.38 ± 0.36 ,0.001
T3 33 (18.8) 58 (33.5) 1.0 (reference)
T2 49 (27.8) 58 (33.5) 1.49 (0.84–2.65)
T1 94 (53.4) 57 (33.0) 2.86 (1.65–4.94)
P for trend ,0.001
Menopausal status
Premenopausal T3 11 (19.0) 21 (30.0) 1.0 (reference)
T2 18 (31.0) 26 (36.6) 1.27 (0.48–3.35)
T1 29 (50.0) 24 (33.8) 2.21 (0.88–5.57)
P for trend 0.074
Postmenopausal T3 14 (15.9) 34 (35.1) 1.0 (reference)
T2 24 (27.3) 31 (32.0) 1.88 (0.82–4.31)
T1 50 (56.8) 32 (33.0) 3.76 (1.73–8.19)
P for trend 0.001
P for interaction 0.410
Age at diagnosis
,55 T3 16 (22.2) 31 (33.7) 1.0 (reference)
T2 18 (25.0) 33 (35.9) 0.96 (0.40–2.26)
T1 38 (52.8) 28 (30.4) 2.50 (1.13–5.50)
P for trend 0.013
55þ T3 17 (16.4) 27 (33.3) 1.0 (reference)
T2 31 (29.8) 25 (30.9) 1.89 (0.84–4.26)
T1 56 (53.9) 29 (35.8) 2.81 (1.29–6.11)
P for trend 0.010
P for interaction 0.947
Family history of breast cancer
No T3 21 (17.7) 42 (30.9) 1.0 (reference)
T2 35 (29.4) 47 (34.6) 1.50 (0.75–2.99)
T1 63 (52.9) 47 (34.6) 2.60 (1.35–4.98)
P for trend 0.003
Yes T3 5 (17.2) 15 (41.7) 1.0 (reference)
T2 7 (24.1) 11 (30.6) 2.08 (0.50–8.66)
T1 17 (58.6) 10 (27.8) 5.73 (1.49–21.97)
P for trend 0.009
P for interaction 0.345
BMI (by median)
Below 26.5 T3 9 (15.3) 18 (25.4) 1.0 (reference)
T2 14 (23.7) 26 (36.6) 1.08 (0.36–3.29)
T1 36 (61.0) 27 (38.0) 2.36 (0.88–6.28)
P for trend 0.044
At or higher 26.5 T3 15 (17.9) 32 (37.2) 1.0 (reference)
T2 25 (29.8) 28 (32.6) 2.05 (0.88–4.77)
T1 44 (52.4) 26 (30.2) 3.98 (1.77–8.95)
P for trend 0.001
P for interaction 0.820
Smoking habit
Never smoker T3 7 (9.5) 27 (32.9) 1.0 (reference)
T2 22 (29.7) 27 (32.9) 3.02 (1.09–8.37)
T1 45 (60.8) 28 (34.2) 6.02 (2.29–15.78)
P for trend ,0.001
Ever smoker T3 18 (25.0) 29 (34.9) 1.0 (reference)
T2 20 (27.8) 27 (32.5) 1.17 (0.50–2.72)
T1 34 (47.2) 27 (32.5) 1.97 (0.89–4.39)
P for trend 0.086
P for interaction 0.084
Alcohol consumption habit
Never drinking alcohol T3 9 (25.0) 13 (40.6) 1.0 (reference)
T2 10 (27.8) 12 (37.5) 1.35 (0.39–4.63)
T1 17 (47.2) 7 (21.9) 3.98 (1.11–14.23)
P for trend 0.033
Ever drinking alcohol T3 17 (15.2) 44 (31.4) 1.0 (reference)
T2 32 (28.6) 46 (32.9) 1.80 (0.87–3.74)
T1 63 (56.3) 50 (35.7) 3.06 (1.55–6.05)
P for trend 0.001
P for interaction 0.826
Multivitamin use
Never or occasional use T3 12 (17.9) 26 (43.3) 1.0 (reference)
T2 26 (38.8) 14 (23.3) 4.68 (1.75–12.58)
T1 29 (43.3) 20 (33.3) 4.04 (1.54–10.57)
P for trend 0.007
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1894Association between methylation levels and breast cancer risk, how-
ever, did not vary by alcohol consumption in our data set, which is
consistent with associations observed in bladder cancer and colorectal
adenoma (21,22). Some studies have shown genomic content of
5-mdC to decline with age (45,48,49), although others show global
methylation levels in human leukocytes or tumor DNA to be indepen-
dent of age (22,33,34), consistent with our ﬁndings. Because the vast
majority of participants in this study were Caucasian, we were unable
to analyze associations between DNA methylation and race. Cigarette
smoking was not associated with global methylation of leukocyte
DNA in agreement with previous studies (22,35,50); however, hypo-
methylation was suggested as a stronger risk factor for breast cancer
risk among non-smokers, which is consistent with ﬁndings from
Moore et al.‘s study (22). Our ﬁnding that associations between meth-
ylation levels and breast cancer risk were more profound among
women with a family history of breast cancer are also consistent with
studies that have noted that genetic factors can affect patterns of
methylation. A recent study investigating longitudinal changes in
global methylation in healthy individuals found familial clustering
of methylation changes (51), suggesting genetic control of mainte-
nance methylation. However, further large studies are needed to con-
ﬁrm the subgroup analysis.
We did not ﬁnd any associations between global methylation levels
and tumor characteristics, consistent with ﬁndings in colorectal and
bladder cancer patients (21,22). Using breast tissue DNA from breast
cancer cases, however, a number of studies (7,8,10,52) have found
signiﬁcant correlations between global hypomethylation and disease
stage, tumor size and histological grade. The inconsistencies between
the results in normal and tumor tissue probably arise from use of
different sources of DNA and/or from differential distributions of
clinical characteristics. In our study, most participants had early-stage
breast cancer (3.9% of American Joint Committee on Cancer stage III,
1.7% of tumor size  2 cm, 24.6% of node involvement and no me-
tastasis as shown in Table I), therefore it may lack the power to assess
associations between global methylation levels and clinical features,
given the small number of advanced breast cancer cases.
Limitations of our study include unexpected distributions of known
breast cancer risk factors among cases and controls, which include
higher family history of breast cancer, higher education and more
frequent use of hormone replacement therapy among controls. One
possible explanation for these observations is differential missing in-
formation among cases, which can affect the association with breast
cancer as a confounder though we did not ﬁnd any signiﬁcant pre-
dictor of global methylation level. Another explanation is that DBBR
participants were all recruited from within a comprehensive cancer
center. Thus, controls within this series included community volun-
teers (50%), employees of RPCI (33%) and family members or
friends of patients (28%). Compared with cases, employee controls
were younger and more highly educated but were not signiﬁcantly
different for family history of breast cancer or for reproductive fac-
tors. Individuals with a family history of cancer might also be more
probably to participate in a ‘cancer study’, which might explain why
controls within the DBBR population were more probably to report
a family history of breast cancer. The association between methyla-
tion levels with breast cancer risk, however, did not differ according to
the source of the control (data not shown), and methylation levels did
not vary between the different groups of controls (data not shown).
Although we assessed potential effect modiﬁcation, this study had
a relatively small sample size for the subgroup analysis and had lack
of power to ﬁnd signiﬁcant interactions on the association between
global methylation and breast cancer risk. We did not assess dietary or
genetic factors involved in 1-carbon metabolism as effect modiﬁers in
this study, although inconsistent associations have been reported in
human studies (21,22,53,54).
This study showed genomic hypomethylation of leukocyte DNA, as
a surrogate of systemic methylation activity, to be associated with
increased breast cancer risk, with associations being particularly
strong among non-smokers and women with a family history of breast
cancer. These ﬁndings provide greater understanding of factors that
may modify breast cancer risk and could lead to development of
a simple non-invasive blood measure of DNA hypomethylation to
identify women at high risk for breast cancer.
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Table IV. Continued
5-mdC Cases, n (%) Controls, n (%) OR (95% CI)
a
Regular use T3 14 (17.3) 31 (27.9) 1.0 (reference)
T2 16 (19.8) 43 (38.7) 0.76 (0.31–1.83)
T1 51 (63.0) 37 (33.3) 2.94 (1.34–6.42)
P for trend 0.001
P for interaction 0.684
T1, ﬁrst tertile; T2, second tertile; T3, third tertile.
aLogistic regression model adjusting for age (continuous variable), race (Caucasian, African-American) and batches.
bT1 methylation level , 4.25; T2 4.25   methylation level , 4.50; T3   4.50.
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Fig. 1. (A) Predictive risk of breast cancer for genomic methylation of
leukocyte after excluding 1% outliers adjusting age, race and batch. (B)
Association between categorical methylation level based on the smoothing
spline as shown (A) and breast cancer.
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